Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Price Target from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus rating of “Buy” from the seven research firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $66.75.

Several research analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. HC Wainwright restated a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, December 17th.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 12,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares of the company’s stock, valued at $9,037,533.84. The trade was a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 15.30% of the company’s stock.

Institutional Investors Weigh In On Arcturus Therapeutics

Several large investors have recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Arcturus Therapeutics by 45.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after purchasing an additional 712,650 shares in the last quarter. Empire Life Investments Inc. purchased a new stake in shares of Arcturus Therapeutics during the third quarter worth $3,498,000. Franklin Resources Inc. raised its position in shares of Arcturus Therapeutics by 54.6% in the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock valued at $2,412,000 after buying an additional 36,714 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Arcturus Therapeutics in the second quarter worth about $596,000. Finally, Squarepoint Ops LLC acquired a new position in Arcturus Therapeutics during the second quarter worth about $718,000. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $17.02 on Wednesday. The stock has a market cap of $461.02 million, a price-to-earnings ratio of -7.67 and a beta of 2.62. The firm has a 50-day moving average of $17.91 and a two-hundred day moving average of $20.97. Arcturus Therapeutics has a 1 year low of $14.30 and a 1 year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. The company had revenue of $41.67 million for the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter last year, the company earned ($0.61) earnings per share. Research analysts expect that Arcturus Therapeutics will post -2.31 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.